The Anti-Aging Antidote to 1 Million Projected Cases of Alzheimer's Disease in US by 2050

Dr. Ronald Klatz, M.D., D.O., President; Dr. Robert Goldman, M.D., Ph.D., D.O.,

The Anti-Aging Antidote to 1 Million Projected Cases of Alzheimer's Disease in US by 2050

One of the biggest burdens in healthcare is in the care of patients with Alzheimer's Disease (AD).

New data from the Alzheimer's Association projects that 14 million, or 18 percent, of the American Baby Boomer population, numbering 79 million in-total, will develop AD or dementia in their lifetime. According to the Alzheimer's Association, if no cure for the disease is found, the US will be faced with 500,000 new cases in 2010 and nearly 1 million a year by 2050.

As the physician co-founders of The American Academy of Anti-Aging Medicine, a non-profit medical society dedicated to the advancement of technology to detect, prevent, and treat aging related disease and to promote research into methods to retard and optimize the human aging process, we urge our clinical colleagues who are on the front-lines treating AD patients to become cognizant of simple and effective natural, non-drug approaches that may beneficially impact the onset and/or progression of this costly and burdensome disease.

The A4M co-sponsors the world's largest scientific conferences in the area of advanced preventative medicine. The next scientific program to convene in the United States and co-sponsored by the A4M is the Spring 2009 Session of the 17th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies. The three-day event takes place April 23-25, 2009 at the Gaylord Palms Hotel & Convention Center in Orlando. Nearly 100 presentations will cover cancer and chronic infectious disease, bio-identical hormone replacement therapy, immune augmentation, office-based aesthetic treatments, stem cell therapeutics, and much more. The conference also features world-renowned researchers and clinicians addressing age-related cognitive decline. Visit www.worldhealth.net to review the program and register online.

We now present a sampling of published peer-reviewed studies of recent therapeutics affecting the progression of Alzheimer's Disease. These types of innovative, effective natural, non-drug therapeutics are typical of content presented at A4M Congresses.

Omega-3 Fatty Acids Beneficial for Cognitive Decline

Chih-Chiang Chiu, from Taipei City Hospital (Taiwan), and colleagues find that omega-3s provide therapeutic benefits for AD patients. The team studied 23 people with mild to moderate AD and 23 people with mild cognitive decline. A segment of each group received 1.8 grams of omega-3 per day for 24 weeks. They found that: "Omega-3 fatty acids may improve general clinical function in patients with mild or moderate Alzheimer's disease and mild cognitive impairment."

Exercise Reverses Alzheimer's Related Mental Decline

Art Kramer, from the University of Illinois (USA), and colleagues, report that 6 months of moderate levels of aerobic activity are sufficient to produce significant improvements in cognitive function, with the most dramatic effects occurring on measures of executive control. The team observed that these improvements are accompanied by altered brain activity measures and increases in prefrontal and temporal grey matter volume that translate into a more efficient and effective neural system. Concluded the team, "We can safely argue that an active lifestyle with moderate amounts of aerobic activity will likely improve cognitive and brain function, and reverse the neural decay frequently observed in older adults. The effects... extend to older adults with dementia."

Vitamin E Improves Longevity of Alzheimer's Patients

In people with AD, Valory Pavlik, from Baylor College of Medicine in Texas, and colleagues found that regular Vitamin E supplementation significantly reduced mortality. The team followed 847 men and women with AD, average age 73.5, for an average of 4.9 years. The study participants were supervised on a high-dose vitamin E supplementation regimen, which was found to reduce their odds of dying by 26 percent.

Age is the single greatest risk factor for Alzheimer's, with the likelihood of developing AD doubling every five years after age 65. Alzheimer's Disease is now the sixth-leading cause of death, killing 72,914 Americans in 2006.

You can learn more about how to beneficially impact the onset and/or progression of Alzheimer's Disease by attending the Spring 2009 Session of the 17th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies. Visit The World Health Network, www.worldhealth.net, the A4M's educational website, to review the program and register online today. While at The World Health Network, join more than 550,000 physicians, health practitioners, and members of the general public and opt-in to receive the A4M's FREE Anti-Aging News Journal.